Manufacturers of innovative healthcare products have historically focused on commercial opportunities in more-developed countries. But increased globalization, coupled with the emergence of new markets with strong growth potential, has created new opportunities—along with new challenges. To be successful in the current environment, Xcenda recommends manufacturers approach market access from a global perspective.

It's never too early to start.

Today's industry leaders are beginning to define the outcomes research strategy from a clinical, economic, and humanistic perspective much earlier in the product development process. To do so effectively, manufacturers must consider the requirements of all major authorities at a global level. So Xcenda created the Global Market Access Network to help clients gather insights from local KOLs in Europe, Asia, and Latin America. These KOLs supplement the advisors who participate in Xcenda's long-standing panel of medical and pharmacy directors from the United States, the Managed Care Network. Apply these insights to clinical trial design to ensure your product submission includes the evidence local markets require.

Learn from local market experts.

Because national and regional entities around the world are instituting reforms designed to ensure the most efficient use of resources, manufacturers must substantiate their product value claims with credible health economic evidence. This is particularly critical to pricing decisions. But with significant variance in the evidence required for health technology assessment and pricing/reimbursement submissions, manufacturers may find it challenging to manage not only the complex market entry requirements, but also local market preferences for how to demonstrate product value. For example, payers in some markets prefer cost-effectiveness models, while others prefer budget impact models. In either case, manufacturers should develop models from a global perspective and then collaborate with local KOLs—such as Xcenda's Global Market Access Network advisors—for guidance on how to adapt economic models for each specific country.

Communicate a consistent message.

When working as a global team, communication is critical. And a Global Value Dossier is an invaluable tool. This single, interactive document summarizes the product's value evidence, the indications, and the markets where it's available. A strong Global Value Dossier ensures consistent messaging to all local commercial affiliates, so all parties can efficiently access the information required for local submissions.

Benefit from our experience.

As a strategic partner to all 10 of the largest global pharmaceutical firms, Xcenda's clients benefit from:

  • Access to the right mix of experts who offer skills and experiences in disciplines as diverse as prospective and retrospective outcomes research, health economics, health technology assessments, pricing, reimbursement, medical communication, and market research
  • One partner to lead the development and implementation of the brand's global market access strategy. We help teams that manage regional or global market access activities, in order to eliminate competing priorities within internal teams and improve understanding and collaboration between departments such as R&D, regulatory affairs, marketing, and brand management
  • Up-to-date knowledge of the different healthcare systems in markets around the world

Turn to Xcenda at every stage of the product life cycle.

Early Development

  • Burden-of-Illness Studies/Publications
  • Disease Burden Models/Publications
  • Health Technology Assessment Surveillance

Later Development

  • Health Technology Assessment Surveillance
  • Comparative Effectiveness Research
  • Cost-effectiveness Models
  • Global Value Dossiers
  • Advisory Boards
  • Retrospective Studies
  • Value Diagnostics
  • Global Market Access/HEOR Strategy

12 to 24 Months Prior to Launch

  • Health Technology Assessment Surveillance
  • Comparative Effectiveness Research
  • Cost-effectiveness Models
  • Budget Impact Models
  • Global Value Dossier
  • Advisory Boards
  • Retrospective Studies
  • Value Diagnostics
  • Global Market Access/HEOR Strategy

Launch

  • Cost-effectiveness Model Publications
  • Budget Impact Model Publications
  • Advisory Boards
  • Prospective Studies

Post-launch

  • Advisory Boards
  • Retrospective Studies
  • Prospective Studies

Late Life cycle

  • Advisory Boards
  • Retrospective Studies

Related Services

Related Case Studies